Compare Abeona Therapeutics Inc (ABEO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $424.33M), while Under Armour Inc Class A trades at $5.24 (market cap $2.48B). The key difference: Under Armour Inc Class A is far larger — about 5.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ABEO | UA | |
|---|---|---|
Market Cap | $424.33M | $2.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $7.88 |
52-Week Low | $4.17 | $3.96 |
Enterprise Value | $279.23M | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Under Armour (UA) trades at $5.925, down 5.2% with bearish technical signals. The company reported mixed Q2 2026 results with an earnings beat but faces revenue declines and negative profitability metrics. Recent news highlights lowered fiscal 2027 revenue outlook due to softer consumer demand in key markets. Cash flow remains negative with significant operational challenges.
The outlook remains challenging with declining revenue trends and negative margins. While analyst consensus shows mixed sentiment, the stock faces headwinds from competitive pressures and execution risks. Investment opportunity exists only for those betting on a successful turnaround despite current fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
